Bodyclinic Sp. z o.o. sp.k.

Warsaw 26 trials 11 recruiting

26 Registered trials

11 Currently recruiting

Organisation

Bodyclinic Sp. z o.o. sp.k.

Location

Warsaw, Poland

Identifier

ORG-100043373

Address

Ul. Ulica Jozefa Sierakowskiego 4/u3, 03-712, Poland

Departments

Bodyclinic Sp. z o.o. Sp. k.
Gastroenterology
Hepatology
Klinika Gastroenterologii i Chorób Wewnętrznych
n/a
NA
PL10009:Gastroenterologia
PL10029: Gastroeneterologia
PL10047_Gastroenterology
private clinic
Wielospecjalistyczna Przychodnia Lekarska BodyClinic

Clinical trials at this site (26)

Search interface

A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending

2025-522511-42-00 Crohn's disease 4
Essentiale® liquid once-daily Phase III study Recruiting

2025-521678-32-00 MASLD (Metabolic Dysfunction-Associated Steatotic Liver 5 2026-03-03
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC Recruiting

2023-503465-33-00 Cholestasis 5 2020-07-03
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Moderately to Severely Active Ulcerative Colitis 5 2025-12-03
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Crohn's disease 4 2025-04-07
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting

2023-509096-16-00 Moderately to Severely Active Crohn’s Disease 6 2024-07-31
Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting

2022-501119-14-01 Ulcerative Colitis 4 2024-04-16
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely… Ended

2023-504719-34-00 Moderate to Severly Active Ulcerative Colitis 5 2023-02-21
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended

2023-504737-41-00 Moderately to Severely Active Crohn's Disease 5 2022-06-10
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Non-alcoholic steatohepatitis (NASH) 5 2021-03-29
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis Ended

2023-510324-77-00 Ulcerative colitis 1 2024-10-20
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03